These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30955188)

  • 1. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.
    Tsuruya K; Shimazaki R; Fukagawa M; Akizawa T;
    Clin Exp Nephrol; 2019 Jun; 23(6):739-748. PubMed ID: 30955188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Fukagawa M; Shimazaki R; Akizawa T;
    Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.
    Tokumoto M; Tokunaga S; Asada S; Endo Y; Kurita N; Fukagawa M; Akizawa T
    PLoS One; 2022; 17(12):e0279078. PubMed ID: 36512619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis.
    Yokoyama K; Shimazaki R; Fukagawa M; Akizawa T;
    Sci Rep; 2019 Apr; 9(1):6410. PubMed ID: 31015494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
    Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
    Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study.
    Schaefer RM; Bover J; Dellanna F; Sanz D; Asensio C; Sánchez González MC; Gross P; Zani V; Carter D; Jehle PM
    Clin Nephrol; 2008 Aug; 70(2):126-34. PubMed ID: 18793528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
    Akizawa T; Ikejiri K; Kondo Y; Endo Y; Fukagawa M
    Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of evocalcet for unmet needs among calcimimetic agents.
    Hamano N; Endo Y; Kawata T; Fukagawa M
    Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
    Akizawa T; Shimazaki R; Fukagawa M;
    PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA
    Tokunaga S; Endo Y; Kawata T
    Nihon Yakurigaku Zasshi; 2019; 154(1):35-43. PubMed ID: 31308348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T;
    Clin Exp Nephrol; 2018 Apr; 22(2):426-436. PubMed ID: 28836058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
    Haq N; Chaaban A; Gebran N; Khan I; Abbachi F; Hassan M; Bernsen R; Abouchacra S
    Int Urol Nephrol; 2014 Jan; 46(1):113-9. PubMed ID: 23529273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
    Reichel H; Braun J
    Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
    Sakai M; Tokunaga S; Kawai M; Murai M; Kobayashi M; Kitayama T; Saeki S; Kawata T
    PLoS One; 2020; 15(4):e0232428. PubMed ID: 32343734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.
    Shigematsu T; Asada S; Endo Y; Kawata T; Fukagawa M; Akizawa T
    PLoS One; 2022; 17(2):e0262829. PubMed ID: 35176038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.